Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Stroke. 2014 Jan 14;45(3):828–834. doi: 10.1161/STROKEAHA.113.003754

Fig 5. SD208 attenuates GMH-induced brain atrophy, brain tissue volume loss, and GMH-induced ventriculomegaly (24 days after GMH).

Fig 5

GMH (N=8) showed significant cerebral atrophy compared to sham-operated animals (N=8). Both acute (N=8) and delayed treatments (N=8) with SD208 ameliorated GMH-induced reduction of whole brain weight (A). GMH caused significant brain tissue loss (B). (C) Representative brain section showing development of ventriculomegaly in all collagenase injected animals and (D) ventricular dilation. SD208 decreased GMH-induced brain tissue loss and attenuated ventricle dilation (* p<0.05 vs. sham, # p<0.05 vs. vehicle). Values are expressed as mean± SD